ImmuPharma plc (LON:IMM – Get Free Report) traded down 1.5% during trading on Monday . The stock traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.62 ($0.04). 27,062,473 shares were traded during mid-day trading, a decline of 13% from the average session volume of 31,089,361 shares. The stock had previously closed at GBX 3.67 ($0.04).
ImmuPharma Stock Performance
The stock has a market cap of £12.86 million, a price-to-earnings ratio of -308.90 and a beta of 1.53. The company has a 50-day simple moving average of GBX 1.48 and a two-hundred day simple moving average of GBX 1.66.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Find and Profitably Trade Stocks at 52-Week Lows
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- 3 Stocks to Consider Buying in October
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
